Webinar Overvi ew
\nThe ACC CV Team Section has invited spe aker Michael Hoosien\, MD\, MSc for an educational session on the updated 2023 Atrial Fibrillation Guidelines. In this webinar\, Dr. Hoosien will di ssect the recommendations that have a high impact on clinical practice.
\n\nKey Objectives/Learning Outcomes:< br>\nUpon completion of this program\, attendees should be able to:
\n- \n
- Describe the new Atrial Fibrillation classificati on scheme which is now based on stages of the disease rather than the dura tion. \n
- Recall the new recommendations as they relate to risk fac tor modification and prevention of thromboembolism. \n
- Understand the updated recommendations for left atrial appendage closure and catheter ablation therapy. \n
- Describe the new recommendations for rate co ntrol and rhythm control. \n
Webinar Participants
\nMichael Hoosien\, MD MSc\, Director Atrial Fibrillation Program\, Pie
dmont Heart Institute
\nChristopher Walsh\, MPAS\, PA-C\, Advanced Prac
tice Education Program Manager\, Piedmont Heart Institute
Credit Information
\n\n\n\nJoint A
ccreditation Statement:
\n
Disclosure/Conflict of Inte
rest Statement:
\nAs a provider jointly accredited by the Accr
editation Council for Continuing Medical Education (ACCME)\, the Accredita
tion Council for Pharmacy Education (ACPE)\, and the American Nurses Crede
ntialing Center (ANCC)\, the American College of Cardiology Foundation (AC
CF) must ensure balance\, independence\, objectivity\, and scientific rigo
r in all of their directly provided or jointly provided/co-provided educat
ional activities. Planners\, presenters\, and other contributors\, in a po
sition to control the content are required to disclose to the audience all
relevant financial relationships he/she and/or his/her spouse or domestic
partner may have\, occurring within the past 24 months\, with any entity
producing\, marketing\, re-selling\, or distributing health care goods or
services consumed by\, or used on\, patients. When an unlabeled use of a c
ommercial product or an investigational use not yet approved for any purpo
se is discussed during an educational activity\, the contributor should di
sclose that the product is not labeled for the use under discussion or tha
t the product is still investigational.
ACCF is committed to pro viding its learners with high-quality activities and materials that promot e improvements and quality in health care and not a specific proprietary b usiness or commercial interest. The intent of this disclosure is not to pr event participation in educational activities by persons with a financial or other relationship\, but rather to provide learners with information on which they can make their own determination whether financial interests o r relationships may influence the education activity.
\n\nACCF asses ses conflicts of interest (COI) with its faculty\, planners\, managers\, s taff\, and other individuals who are in a position to control the content of certified activities. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors\, ACCF education staff\, and members of the Accreditation Compliance Workgroup (ACWG) thro ugh a process that includes appropriate peer review for fair balance\, sci entific objectivity and validity\, and patient care and safety recommendat ions.
\n\nACCF has taken the necessary steps to ensure that all rele vant financial relationships have been mitigated.
\n\nPlease note AC CF staff and the ACWG members involved with this activity have nothing to disclose.
\n\nSee Program Committee and Faculty rows below for l anguage communicating disclosure information
\n\nPlanne
r/Faculty Disclosure information:
\nChristopher Walsh\, MPAS\,
PA-C\,
\nSarah Sloane\, PhD\, DNP\, APRN\, FNP-BC\, CCRN\, CNE
\nMi
chael Hoosien\, MD MSc